Tvardi Therapeutics Inc TVRD.OQ TVRD.O is expected to show a fall in quarterly revenue when it reports results on March 9 (estimated) for the period ending December 31 2025
LSEG's mean analyst estimate for Tvardi Therapeutics Inc is for a loss of 65 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Tvardi Therapeutics Inc is $10.00, about 148.8% above its last closing price of $4.02
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -1.01 | -1.00 | -0.59 | Beat | 41 |
Jun. 30 2025 | -0.65 | -0.57 | -1.00 | Missed | -74.9 |
Mar. 31 2025 | -0.35 | -0.35 | -3.22 | Missed | -820 |
-5.04 | |||||
Sep. 30 2024 | -8.88 | -8.28 | Beat | 6.8 | |
Jun. 30 2024 | -9.64 | -9.86 | -13.32 | Missed | -35 |
Mar. 31 2024 | -14.34 | -14.33 | -20.16 | Missed | -40.7 |
Dec. 31 2023 | -15.70 | -14.83 | -21.24 | Missed | -43.2 |
This summary was machine generated March 6 at 20:39 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)